Erasca (NASDAQ:ERAS) Shares Gap Down – Here’s Why

Erasca, Inc. (NASDAQ:ERAS – Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $14.22, but opened at $13.13. Erasca shares last traded at $13.9160, with a volume of 2,306,222 shares changing hands.

Key Headlines Impacting Erasca

Here are a few of the latest headlines about ERAS:

  • Positive Sentiment: At the 32 mg daily dose, ERAS-0015 produced confirmed response rates of 44% in second-line-or-later pancreatic cancer patients with KRAS G12X mutations, 69% in the G12D/G12V pancreatic subgroup, and 60% in a small group of previously treated KRAS-mutant lung cancer patients. Erasca said the drug was generally well tolerated, with mostly low-grade side effects. Erasca Phase 1 data
  • Positive Sentiment: The company plans to begin a potentially registration-enabling lung cancer trial and a Phase 3 pancreatic cancer trial in 2027. It also reported preliminary activity and favorable tolerability for ERAS-4001, another investigational drug, and expects to test it in combination with ERAS-0015. These developments could expand the pipeline’s potential, although they remain early-stage. Trial update
  • Neutral Sentiment: A Seeking Alpha contributor upgraded Erasca to “Buy,” citing ERAS-0015’s clinical progress and the company’s Bristol Myers Squibb collaboration. This is an individual analyst opinion, not a company announcement or a consensus rating. Seeking Alpha analysis

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Bank of America increased their target price on Erasca from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. HC Wainwright increased their target price on shares of Erasca from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a research report on Tuesday, September 8th. Leerink Partners started coverage on shares of Erasca in a research note on Tuesday, November 17th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, Guggenheim raised their target price on shares of Erasca from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.17.

View Our Latest Analysis on ERAS

Erasca Stock Down 4.3%

The stock has a 50 day moving average price of $14.77 and a two-hundred day moving average price of $15.35. The firm has a market cap of $4.78 billion, a PE ratio of -13.75 and a beta of 0.68.

Erasca (NASDAQ:ERAS – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). As a group, equities analysts anticipate that Erasca, Inc. will post -0.53 earnings per share for the current year.

Institutional Trading of Erasca

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. a16z Capital Management L.L.C. acquired a new stake in Erasca in the 3rd quarter valued at $20,982,000. Algert Global LLC raised its position in shares of Erasca by 145.6% during the third quarter. Algert Global LLC now owns 77,700 shares of the company’s stock worth $1,139,000 after purchasing an additional 46,060 shares during the period. Virtu Financial LLC purchased a new position in Erasca during the third quarter valued at approximately $172,000. New York State Common Retirement Fund raised its holdings in shares of Erasca by 9.2% during the 3rd quarter. New York State Common Retirement Fund now owns 76,859 shares of the company’s stock valued at $1,127,000 after purchasing an additional 6,500 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Erasca by 13.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 4,348,033 shares of the company’s stock worth $63,742,000 after acquiring an additional 525,920 shares during the last quarter. Hedge funds and other institutional investors own 67.78% of the company’s stock.

Erasca Company Profile

(Get Free Report)

Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.

Recommended Stories

Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.